Fibulink Syndesmosis Repair System With Early Full-Weight Bearing

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age22+
SponsorMaimonides Medical Center

About this trial

The purpose of the study is to evaluate the ability of the Fibulink Syndesmosis Repair System to maintain reduction of the ankle syndesmosis. Appropriate reduction of the syndesmosis is critical due the changes in tibiotalar contact pressure observed in cadaveric studies.6,7 Malreduction and instability of the distal tibiotalar joint can lead to chronic instability, increased articular damage and ultimately degenerative arthritis.7,8 Medial to lateral translation of distal tibia and fibula of 2 mm or more has been considered pathologic.9 Earlier biomechanical study demonstrated the Fibulink system is superior in maintaining displacement of less than 2 mm.4 Given the improved strength, we also look to evaluate the outcomes of initiating full weight bearing (100%) with Controlled Ankle Motion (CAM) boot at 4 weeks postoperatively. One of the big limitations for trans-osseous screw fixation is delayed weight bearing due to risk of screw breakage.1 Suture button technique allowed for early weight bearing with average of 6 weeks postoperatively using TightRope.2,10-12By initiating full weight bearing (100%) with CAM boot at 4 weeks postoperatively, this would be a significant improvement in current clinical practice.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

ankle fracture with syndesmotic disruption as assessed with intra-operative cotton test.

Syndesmotic sprain (without fractures)

Bimalleolar equivalent ankle fractures

Bimalleolar ankle fractures

Disqualifiers

1) previous ankle surgery, 2) active local infection about the ankle, 3) chronic ankle deformity secondary to trauma or congenital, 4) ligamentous laxity, 5) pathologic fractures, 6) peripheral vascular disease, 7) peripheral neuropathy, 8) diabetes neuropathy and charcot, 9) open fractures, 10) poly trauma, 11) inability to provide informed consent, 12) symptomatic ankle osteoarthritis, 12) retained hardware, 13) pregnant, 14) metabolic bone disease, 15) history of chronic steroid use, 16) mal-reduced ankle fractures

Trial design

Design model

Parallel

Treatments tested in this trial

  • Early Weight Bearing

    Other intervention

    Full weight bearing (100%) initiated at 4 weeks postoperatively

  • Normal Weight Bearing

    Other intervention

    Full weight bearing (100%) initiated at 6 weeks postoperatively

Treatment groups

56 Participants
are divided into 2 treatment groups
Group A: 1) Early Full Weight BearingExperimental treatment 1 intervention
Group B: 2) Normal Full Weight BearingActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

6 Month Reduction Quality

The primary objective is to evaluate the reduction and maintenance of the reduction of ankle syndesmosis in 6 months after initiating full weight bearing (100%) at 4 weeks or 6 weeks postoperatively. This will be determined based on comparing the tibiofibular overlap, tibiofibular clear space and medial clear space preoperative values.

Time frame
6 Months

Secondary outcomes

1

2 Week Reduction Quality

Reduction and maintenance of the reduction of the ankle syndesmosis at 2 weeks based on the tibiofibular overlap, tibiofibular clear space and medial clear space preop values.

Time frame
2 Weeks
2

4-6 Week Reduction Quality

Reduction and maintenance of the reduction of the ankle syndesmosis at 4-6 weeks based on the tibiofibular overlap, tibiofibular clear space and medial clear space preop values.

Time frame
4-6 Weeks
3

8-10 Week Reduction Quality

Reduction and maintenance of the reduction of the ankle syndesmosis at 8-10 weeks based on the tibiofibular overlap, tibiofibular clear space and medial clear space preop values.

Time frame
8-10 Weeks
4

3 Month Reduction Quality

Reduction and maintenance of the reduction of the ankle syndesmosis at 3 months based on the tibiofibular overlap, tibiofibular clear space and medial clear space preop values.

Time frame
3 Months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Maimonides Medical Center

Lead sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborator